The Prostate HessMap™
Malcolm Gadwell explains the issues currently facing prostate cancer diagnosis
Prostate Cancer’s Diagnostic Dilemma
Today, cancer is most commonly diagnosed when a patient develops clinical symptoms or if it is detected by palpation. If a screening methodology today detects an early lesion, it is often difficult to determine whether the tumor is malignant or benign, dormant or aggressive without multiple repeated invasive procedures. Therapy initiated during this cloud of diagnostic uncertainty frequently led to irreversible debilitating outcomes for too many patients.
The Prostate Question
We are working on the Prostate Cancer HessMap™ . Clinical trials will open in 2021. Its launch will help men with localized cancer and early signs of aggressive features in the biopsy histology decide when, or if, to undergo transurethral resection of the prostate (TURP). For these men, our Prostate HessMap™ assay will provide a periodic, non-invasive, accurate profile of their prostate’s evolving biology - whether, and at what speed the cancer progresses or if it remains dormant - giving them diagnostic certainty to safely ‘wait to see’ or pursue other therapies.
Our Prostate HessMap™ Assay will be available for clinical applications and the Companion Diagnostic (CDx) market.
The HessMap™ Solution
A robust, reliable assay based on platelet sequestered proteins that definitely indicate disease state and status…without invasion.
Our Revolutionary HessMaps™ Platform is a robust disease profiling assay
Shows the entire cancer-relevant protein landscape rather than selected protein biomarkers.
Provides an organ and person specific platelet protein array.
Groups platelet-associated proteins by their functions and impacts. E.g. angiogenesis modulating, inflammatory, growth promoting, apoptosis inducing. etc.
Shows changes in the platelet protein landscape relevant to disease stage and progression.
Allows for real time evaluation of the efficacy and patient response to therapy - guiding patient treatment and clinical trial enrollment and design.
For prostate cancer patients, waiting confidently, is now possible.
More information on Prostate Cancer including available clinical trials, is available at the Prostate Health Education Network.
The HessMap™ Assay test is not currently commercially available. It will be available only to participants of Hessian Labs clinical studies.
The HessMap™ test is intended to compliment not replace US recommended guidelines for cancer screening.
Future Cancer indications to include:
Pancreatic
Kidney
Lung